2005
May 31, 2005
Announces Director Change
May 25, 2005
Proxy Statement and Notice of Meeting
May 25, 2005
Proxy Statement for AGM
May 25, 2005
Form of Proxy
May 19, 2005
Enters Agreement with ACT
2004
July 28, 2004
Announces Operational Restructuring
Click Icon below to download a free
version of Adobe Acrobat Reader
June 22, 2004
Announces Issuance of a U.S. Patent Covering Methods for Producing Cloned Animals
March 18, 2004
SCHEDULE 11
Notification of Interests of Directors and Connected Persons
March 16, 2004
TranXenoGen, Inc.
Final Results for the Year Ended 31 December 2003
January 13, 2004
TranXenogen, Inc., Joins CREST Electronic Settlement System
January 07, 2004
TranXenogen, Inc., Engages Madison Keats™ to Assist In Identifying
licensing Partner for ANUP and to secure additional financing
2003
December 01, 2003
TranXenoGen, Inc., Receives U.S. Notice of Allowance for Patent
Relating to Genetic Manipulation of Male Germ Cells
NOVEMBER 24, 2003
SCHEDULE 11
Notification of Interests of Directors and Connected Persons
NOVEMBER 13, 2003
Announces Progress on Anti-Neoplastic Urinary Protein Program
SEPTEMBER 04, 2003
TranXenoGen, Inc. Interim Results for the Six Months Ended 30 June 2003
July 07, 2003
TranXenoGen, Inc. Dealings By Directors
June 30, 2003
TranXenoGen, Inc. Appointment of Insinger as Nominated Advisor and Broker
June 18, 2003
TranXenoGen, Inc. Enters Into Evaluation Agreement
MAY 05, 2003
TranXenoGen - Annual General Meeting Statement
MARCH 13, 2003
TranXenoGen - Final Results for the Year Ended 31 December 2002
2002
DECEMBER 05, 2002
TranXenoGen - Appointment of Non-Executive Chairman
NOVEMBER 13, 2002
SCHEDULE 11
Notification of Interests of Directors and Connected Persons
OCTOBER 28, 2002
SCHEDULE 11
Notification of Interests of Directors and Connected Persons
SEPTEMBER 05, 2002
Interim Results for the Six Months Ended 30 June 2002
JULY 03, 2002
TranXenoGen - Statement re: share price movement
JUNE 19, 2002
TranXenoGen - Change of Auditors
MAY 30, 2002
TranXenoGen - Announces Successful Expression of
Monoclonal Antibodies in Eggs Proof of Principle Achieved
MARCH 06, 2002
TranXenoGen - Final Results for the Year Ended
31 December 2001 Review of Strategic Direction
2001
DECEMBER 05, 2001
SCHEDULE 11
Notification of Interests of Directors and Connected Persons
NOVEMBER 29, 2001
SCHEDULE 11
Notification of Interests of Directors and Connected Persons
NOVEMBER 21, 2001
TranXenoGen - Moves into new facility
OCTOBER 22, 2001
TranXenoGen - Appointment of new CEO
SEPTEMBER 07, 2001
TranXenoGen Research/Evaluation Agreement with Amgen for
Monoclonal Antibody Production
SEPTEMBER 07, 2001
Interim Results for the Six Months Ended 30 June 2001;
Collaboration agreement with Amgen
AUGUST 31, 2001
Change of Interim Results Announcement Date
JULY 30, 2001
Interim Results Announcement Date
MARCH 06, 2001
TranXenoGen Announces Collaboration with Abbott Laboratories
to Pursue Innovative Monoclonal Antibody Production
MARCH 06, 2001
Preliminary results for year ended 31 December 2000
MARCH 02, 2001
TranXenoGen Licenses Novel Anti-Cancer Protein
JANUARY 31, 2001
TranXenoGen Announces the Development
of Germline Transgenic Chickens
JANUARY 23, 2001
TranXenoGen Purchases 80,000 Square Foot Research and
Manufacturing Facility
JANUARY 09, 2001
Exercise of Class C Preferred Stock
2000
OCTOBER 16, 2000
TranXenoGen Announces Two Collaborations to Evaluate
Its Monoclonal Antibody Production Technology
JUNE 19, 2000
TranXenoGen- Initial Public OFFERING
Second Generation Transgenics Company to list on AIM
MARCH 01, 2000
GeneMedix in Global Licensing Deal with TranXenoGen Inc.
JANUARY 28, 2000
TranXenoGen and U.S. Transgenics Announce Joint Venture to Produce HSA
And a Collaboration for Additional Proteins
BACK TO THE TOP
ABOUT TRANXENOGEN I WHY AVIAN TRANSGENICS I INVESTOR RELATIONS I ANNUAL REPORT
NEWS CENTER I CAREERS I CONTACT US I DIRECTIONS

TRANXENOGEN, INC. • PO BOX 21 • NORTHBORO, MA. 01532 • 508 842 5036

© COPYRIGHT TRANXENOGEN, INC. 2002